|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
As a collaboration of the COVAR clinical trial group (France), and the ENIGMA consortium for investigating breast cancer gene variants, this study evaluated 8 <i>BRCA2</i> variants resulting in complete deletion of exon 3.
|
29707112 |
2018 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
EBNA-2 and LMP-1 immunohistochemistry were negative in all breast cancer and control specimens.
|
21207256 |
2011 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
|
25857409 |
2014 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
Our group has studied EBV association with breast cancer by using in situ hybridization for detecting nonpolyadenylated EBV RNA (EBERs), along with using protein localization technique of immunohistochemistry, studying the EBV nuclear antigen 1 (EBNA1) and the latent membrane proteins (LMP1 and LMP2A).
|
12218080 |
2002 |
|
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because the effects of LMP1 have been most closely studied in human Burkitt Lymphoma (BL) cell lines retaining a tumor biopsy-like phenotype in vitro, we have examined the response of a panel of such lines to CD40 ligation.
|
10092782 |
1999 |
|
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infection with Epstein-Barr virus (EBV) and its encoded latent membrane protein 1 (LMP1) play oncogenic roles in Burkitt's lymphoma (BL).
|
25591797 |
2015 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, to identify targets of LMP1 that are regulated through PARP1, LMP1 was ectopically expressed in an EBV-negative Burkitt's lymphoma cell line.
|
30395643 |
2018 |
|
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unusually high frequency of a 69-bp deletion within the carboxy terminus of the LMP-1 oncogene of Epstein-Barr virus detected in Burkitt's lymphoma of Turkish children.
|
9823956 |
1998 |
|
Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, del-LMP-1 were found in 1 of 5 (20%) Burkitt lymphomas (BL); 17 of 24 (71%) aggressive non-Hodgkin's lymphoma (agg-NHL), and 2 of 10 (20%) reactive lymphoid proliferations.
|
8704180 |
1996 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetylase inhibitor-stimulated endogenous LMP-1 also induced CCL20 expression in an EBV-positive BL cell line.
|
16409294 |
2006 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have shown that Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) is uniquely able to up-regulate the expression of the peptide transporters (referred to as TAP-1 and TAP-2) and major histocompatibility complex (MHC) class I in Burkitt's lymphoma (BL) cell lines.
|
11799186 |
2002 |
|
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMP promoter cat gene constructs were more active in a Burkitt's lymphoma cell line latently infected with the B95 EBV strain than in the same cells latently infected with the P3HR1 EBV strain.
|
2157069 |
1990 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using an EBV-negative Burkitt's lymphoma cell line in which the expression of EBV latent membrane protein 1 (LMP1) is inducibly regulated by tetracycline, we demonstrate that LMP1 expression coincides with a dramatic increase in the level of bfl-1 mRNA.
|
10864681 |
2000 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results suggest that expression of LMP1 at levels which are compatible with immortalization of normal B-cells antagonizes the ability of BL cells to grow in vitro and in vivo, and illustrate a possible mechanism by which down-regulation of this viral antigen may favor tumorigenicity in EBV-carrying BLs.
|
1322379 |
1992 |
|
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines.
|
16332968 |
2006 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Latency III (Lat III) in group III BL and EBV-transformed lymphoblastoid cell lines (LCLs) is characterized by expression of EBNAs 1, 2, 3a, 3b, 3c, and -LP from mRNAs driven by the Cp or Wp promoter and of the latent membrane proteins (LMPs 1, 2A, and 2B) from mRNAs driven by the LMP promoters.
|
1310556 |
1992 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Z-43 cells expressed high levels of LMP1 (immunoblot) and lymphotoxin (ELISA); the EBV-positive Burkitt's lymphoma line Daudi expressed neither LMP1 nor lymphotoxin.
|
14523478 |
2003 |
|
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies of EBV-converted and stably transfected BL cell lines demonstrated that the EBV gene LMP-1 is neither necessary nor sufficient to block the TGF-beta1 response.
|
10811940 |
2000 |
|
Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epstein-Barr virus (EBV) and its encoded oncoprotein, latent membrane protein 1 (LMP1), are closely associated with the transformation of nasopharyngeal carcinoma (NPC) and Burkitt's lymphoma (BL).
|
26244812 |
2015 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In type I Burkitt lymphoma (BL) cell lines and in the conditional lymphoblastoid cell line (LCL) ER/EB2-5, IL-21 potently activated STAT3 and induced the expression of LMP-1, but not EBNA-2.
|
20080768 |
2010 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The latent membrane protein 1 (LMP1) is likely to play a determinant role in this process since this EBV encoded protein has oncogenic properties and is usually expressed in EBV-associated lymphoproliferative diseases (LPD), except Burkitt's lymphoma.
|
9160892 |
1997 |
|
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The LMP1 and EBNA2 genes were transiently expressed from heterologous promoters in two human T-cell lines (HPB-ALL and Jurkat), two human cell lines of the myeloid lineage (K562 and U937), one type I Burkitt's lymphoma cell line (Rael) and in human primary T cells and B-cell chronic lymphocytic leukemia cells.
|
8093369 |
1993 |
|
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we show that LMP1 negatively regulates a major oncogene, TCL1, in diffuse large B-cell lymphoma (DLBCL) and BL cells.
|
19966860 |
2010 |
|
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that IL-10 was specifically induced by the EBV-latent membrane protein 1 (LMP1) in Burkitt's lymphoma (BL) cell lines BL2 and BL41.
|
11162833 |
2001 |